OSCR
Oscar Health, Inc.
OSCR has the edge over SERA overall, supported by stronger fundamentals.
SERA
Sera Prognostics, Inc.
SERA trails on the overall score without a compensating advantage in the available component scores.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SERA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SERA's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SERA PE Valuation
SERA has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SERA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SERA's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SERA on earnings quality, reporting a profit while its opponent remains loss making.
SERA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | +$0.11 |
| Q2 2026 | -$0.66 | +$0.19 |
| Q1 2026 | -$0.64 | +$0.30 |
| Q4 2025 | -$0.67 | +$0.32 |
| Q3 2025 | -$0.77 | +$0.22 |
| Q2 2025 | -$0.85 | +$0.13 |
| Q1 2025 | -$0.94 | +$0.13 |
| Q4 2024 | -$0.99 | +$0.17 |
SERA is still losing money, but far less than before: $0.66 per share over the past year, against $1.43 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SERA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SERA on profitability, with a higher operating margin.
SERA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42K | +163% |
| Q2 2026 | $30K | +76% |
| Q1 2026 | $14K | -63% |
| Q4 2025 | $10K | -58% |
| Q3 2025 | $16K | -45% |
| Q2 2025 | $17K | -29% |
| Q4 2024 | $24K | -41% |
| Q3 2024 | $29K | -31% |
SERA's revenue is recovering but still below its 2023 peak: $42,000 last quarter, up 163% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -21160% | +34966 points |
| Q2 2026 | -33347% | +21477 points |
| Q1 2026 | -66857% | -42515 points |
| Q4 2025 | -89540% | -50278 points |
| Q3 2025 | -56125% | -25566 points |
| Q2 2025 | -54824% | -16269 points |
| Q1 2025 | -24342% | N/A |
| Q4 2024 | -39263% | -17682 points |
SERA's operating margin was −21160% last quarter, up 34965 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SERA on cash generation, producing positive trailing cash flow while its opponent burns cash.
SERA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.4M | -$843K |
| Q2 2026 | -$6.3M | -$573K |
| Q1 2026 | -$8.8M | -$1.2M |
| Q4 2025 | -$6.5M | -$182K |
| Q3 2025 | -$6.6M | +$432K |
| Q2 2025 | -$5.8M | +$181K |
| Q1 2025 | -$7.6M | -252% |
| Q4 2024 | -$6.3M | +$513K |
SERA has burned cash in almost every quarter: −$29M over the past year, against −$26M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SERA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +313K shares |
| 1 year | +2.6% | +1.3M shares |
| 3 years | +62% | +19.5M shares |
| 5 years | +66% | +20.3M shares |
| Available history | +180% | +32.7M shares |
SERA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SERA Net Leverage
SERA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SERA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 57.3 | Neutral |
SERA's weekly RSI is 46 (neutral) and its Stochastic is 57 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SERA PE vs Healthcare Sector
SERA has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SERA on trend strength, trading above more of its moving averages.
SERA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 3.9% below |
| 20 week MA | $2.05 | 3.4% below |
| 50 week MA | $2.29 | 14% below |
| 100 week MA | $2.97 | 33% below |
| 200 week MA | $4.19 | 53% below |
SERA is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SERA on returns for 2026, with the stronger performance.
SERA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.0 | $8.00 | -27% |
| 2022 | $8.00 | $1.60 | -80% |
| 2023 | $1.60 | $5.98 | +274% |
| 2024 | $5.98 | $8.00 | +34% |
| 2025 | $8.00 | $3.52 | -56% |
| 2026 YTD | $3.52 | $1.98 | -44% |
SERA's yearly returns have swung widely, from +274% in 2023 to −80% in 2022. It's down 44% so far in 2026.